Eric Benevich - Feb 13, 2023 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Commercial Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Stock symbol
NBIX
Transactions as of
Feb 13, 2023
Transactions value $
$0
Form type
4
Date filed
2/15/2023, 06:06 PM
Previous filing
Feb 8, 2023
Next filing
Aug 23, 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Stock Option Award $0 +51.8K $0.00 51.8K Feb 13, 2023 Common Stock 51.8K $103.52 Direct F1
transaction NBIX Restricted Stock Unit Award $0 +8.33K $0.00 8.33K Feb 13, 2023 Common Stock 8.33K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F2 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
F3 The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027.